Teprotumumab
REQUEST MORE INFO
Price:
US$464.00
(Size: 100 µg)
Click on the image to see the image legend
Teprotumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. 8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED. 7 Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Target |
IGF1R/CD221 |
Clonality |
Monoclonal |
Reactivity |
Human |
Expression |
Recombinant |
Tested Applications |
ELISA, WB |
Host |
Human |
Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
Conjugation |
Unconjugated |
Isotype |
IgG1-ND |
Form |
Liquid |
Purity |
> 95% |
Purification |
Purified from cell culture supernatants by Protein A/G chromatography. |
Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Buffer |
0.01 M PBS. pH 7.4. |
CAS Number |
1036734-93-6 |
Concentration |
Batch-dependent, typically between 0.5-2.0 mg/ml. |
Availability |
Shipped within 7-12 working days. |
Note |
This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Research Articles on IGF1R/CD221